Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

Similar documents

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent


VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

Fig. 1 Chemical structure of KW-1070

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

VOL.42 S-1

Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

CHEMOTHERAPY

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

Fig. 1 Chemical structure of norfioxacin (AM-715)

VOL. 34 S-2 CHEMOTH8RAPY 913

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

Fig. 1 Chemical structure of DL-8280

CHEMOTHERAPY

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

CHEMOTHERAPY MAY. 1988

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus


Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

Table1MIC of BAY o 9867 against standard strains

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad


CHEMOTHERAPY

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -

CHEMOTHERAPY



CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote


988 CHEMOTHERAPY NOV. 1971


CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

400 CHEMOTHERAPY JAN Table 1 Cases of drop outs

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

VOL.27 S-5 CHEMOTHERAPY Table 1 Clinical evaluations of cefamandole on UTI (1) Benign prostatic hypertrophy (2) Transurethral resection of bladder tum

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz


1272 CHEMOTHERAPY MAR. 1975

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

Title 神経因性膀胱にともなう排尿障害に対する塩酸ブナゾシンの臨床効果 - 二重盲検比較試験による検討 - 小柳, 知彦 ; 富樫, 正樹 ; 丸, 彰夫 ; 折笠, 精一 ; 相馬, Author(s) 崎, 淳 ; 安田, 耕作 ; 阿曽, 佳郎 ; 本問, 之夫 ; 三宅, 弘厚生 ; 熊

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG


明海大学歯学雑誌　３７‐２／１．秦泉寺


Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection




日本化学療法学会雑誌第59巻第5号

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega


日本化学療法学会雑誌第65巻第4号

CHEMOTHERAPY FEB Table 1 Background of volunteers

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

CHEMOTHERAPY JAN Fig. 1 Structure of cephradine

Title 外傷性脊髄損傷患者の泌尿器科学的研究第 3 報 : 上部尿路のレ線学的研究並びに腎機能について Author(s) 伊藤, 順勉 Citation 泌尿器科紀要 (1965), 11(4): Issue Date URL



VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin

04-c-„FŒ{›xŒ¾-4.01


208 ( 2 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 Cefditoren pivoxil (CDTR-PI) MS MS 10%

Key words: Norfloxacin (NFLX), Infectious enteritis, Double-blind method

Key words: Antibodies to Leptospira, Tokyo, Uveitis

日本化学療法学会雑誌第60巻第4号

Some Investigations of Urinary Candidiasis Chujiro YAMAMOTO, M. D., Mitsushi MIZUTANI, M. D. and Tokuro SATO, M. D. From the Department of Urology, Ni

Therapy for Asthenopia in Cases of Convergence Insufficiency Hiroko TAKASAKI, C.O.J., Nobuko INAGAMI, C.O.J., and Kayoko TAKENAWA, C.O.J.. Orthoptic c

Fig. 1 Chemical structure of Flurbiprofen Molecular formula : C1S H13 F02 Molecular weight : Chemical name : 2-( 2 -fluoro - 4 -biphenyly1 ) pr



Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination





VOL.39 S-3


CHEMOTHERAPY SEPT. 1970

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen

VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity

VOL. 21 NO. 2 CHEMOTHERAPY 395

CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation



VOL. 43 NO. 4

VOL.27 CHEMOT S-1 HERAPY 185 に感 性 を示 して い たが,臨 床 的 に は無 効 で あ った 本 症 る 細 菌学 的 に も検 討 した が,起 炎菌 と考 え られ る細 菌 を 例 で は 基礎 疾 患 と して縦 隔 洞腫 瘍 が あ り,既 に 副 腎

原 著 放射線皮膚炎に対する保湿クリームの効果 耳鼻科領域の頭頸部照射の患者に保湿クリームを使用して * 要旨 Gy Key words はじめに 1 70Gy 2 2 QOL

Transcription:

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

Table 1. Clinical summary of acute uncomplicated cystitis patients treated with 7432-S UTI : Criteria by the UTI Committee Dr : Dr's evaluation

Table 2. Overall clinical efficacy of 7432-S in acute uncomplicated cystitis Table 3 Bacteriological response to 7432-S in acute uncomplicated cystitis regardless of bacterial count

Table 4. Relation between MIC and bacteriological response to 7432-S treatment Table 5. Strains * appearing after 7432-S treatment in acute uncomplicated cystitis

Table 6-1. Clinical summary of complicated UTI patients treated with 7432-S C.C.P. : Chronic complicated pyelonephritis C.C.C. : Chronic complicated cystitis B.P.H. : Benign prostatic hypertorophy V.U.R. : Vesicoureteral reflux

Table 6-2. Clinical summary of complicated UTI patients treated with 7482-S C.C.C. : Chronic complicated cystitis Before treatment UTI : Criteria by the UTI committee Dr : Dr's evaluation

Table 6-3. Clinical summary of complicated UTI patients treated with 7432-8 C.C.C. : Chronic complicated cystitis B.P.H. : Benign prostatic hypertorophy Table 7. Overall clinical efficacy of 7432-S in complicated UTI

Table 8. Overall clinical efficacy of 7432-S classified by the type of infection

Table 9. Relation between MIC and bacteriological response to 7432-S treatment

Table 10. Bacteriological response to 7432-S in complicated UTI Table 11. Strains* appearing after 7432-S treatment in complicated UTI

Table 12. Difference of overall clinical efficacy of 7432-S

CLINICAL STUDIES ON 7432-S IN THE UROLOGICAL FIELD SOICHI ARAKAWA, SHINSUKE TAKAGI, HIROSHI MAEDA, SYOJIN KA, AKIRA FUJII, TAKEKI HAMAGUCHI and SADAO KAMIDONO Department of Urology, Kobe University School of Medicine 7, Kusunoki-cho, chome, Chuo-ku, Kobe 650, Japan KEIICHI UMEZU GAKU KAWABATA and JOJI ISHIGAMI Department of Urology, Kobe National Hospital, Kobe, Japan HIROSHI YAMAZAKI Department of Urology, Miki City Hospital HIDEO OSHIMA, HITOSHI NAGATA and TAKAHIRO IWAMOTO Department of Urology, Hyogo Prefectural, Kakogawa Hospital NOBUO KATAOKA, YOSHIMI MATSUSHITA and KIYOHIKO GOTO Department of Urology, Nishiwaki City Hospital We studied the clinical efficacy and safety of a new orally administered cephem antibiotic, 7432-S, on 67 patients with urinary tract infections (UTI). The results were as follows: (1) Acute uncomplicated cystitis (20 patients) Twenty patients with acute uncomplicated cystitis were given 200 mg of 7432-S divided into two equal oral doses daily for 3 days. The drug was judged to be effective by the physicians in 90% of the cases. In 18 patients complying with the Japanese UTI Drug Effect Evaluation Standards, 13 showed "excellent", and "moderate" in 5. There was no case where the drug had no effect, showing 100% of overall effectiveness rate. The eradication rate was 100% (21/21) and 12 bacterial strains were observed after the treatment. (2) Complicated urinary tract infections (47 patients) Fourty-seven patients with complicated UTI were given 200-600 mg of 7432-S divided into two or three equal oral doses daily for five days. The physicians evaluated the response in 45 patients with an efficiency rate of 53%. Of 38 patients complying with the Japanese UTI criteria, 14 showed "excellent", "moderate" in 12 and "poor" in 12, an overall efficiency rate of 68%. The eradication rate was 82% (42/45) and 13 bacterial strains were observed after the treatment. (3) Safety (67 patients) No patients had subjective or objective adverse reactions. Abnormal laboratory findings (neutropenia, increased levels of GOT, GPT, ALP and ALP, BUN) were found in three patients, but these were mild and transient.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック